Prasad Reddy
Psychiatry · Visalia, CANPI 1588862262
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.7% of the total across 351 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 351 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Supernus Pharmaceuticals, Inc.$765
- AbbVie$669
- Otsuka America Pharmaceutical, Inc.$472
- Takeda Pharmaceuticals U.S.A., Inc.$392
- plus $2K from 16 others
What the payments were for
- Food & beverage$6,53594%
- Education$4426%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 62 | $1,318 |
| Teva Pharmaceuticals USA, Inc. | 65 | $1,165 |
| Supernus Pharmaceuticals, Inc. | 43 | $765 |
| AbbVie(2 entities) | 36 | $669 |
| Otsuka America Pharmaceutical, Inc. | 15 | $472 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $392 |
| Ironshore Pharmaceuticals Inc. | 18 | $349 |
| Lundbeck LLC | 18 | $303 |
| Johnson & Johnson | 10 | $289 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $270 |
| Axsome Therapeutics, Inc. | 6 | $261 |
| Neurocrine Biosciences, Inc. | 8 | $157 |
| Indivior Inc. | 6 | $113 |
| Corium, LLC | 6 | $103 |
| E.r. Squibb & Sons, L.L.C. | 5 | $100 |
| Vanda Pharmaceuticals Inc. | 3 | $58 |
| OWP Pharmaceuticals, Inc. | 2 | $47 |
| Collegium Pharmaceutical, Inc. | 2 | $42 |
| Avanir Pharmaceuticals, Inc. | 2 | $40 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Merck | 1 | $19 |
| Eisai Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$256
- ABILIFY ASIMTUFII$131
- Auvelity$128
- CAPLYTA$125
- UZEDY$102
- SPRAVATO$101
How this compares
$6,977 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 44 | $349,494 |
| Austedo XrDeutetrabenazine | 39 | $287,187 |
| LybalviOlanzapine/Samidorphan Malate | 77 | $118,515 |
| VraylarCariprazine Hcl | 41 | $53,150 |
| RexultiBrexpiprazole | 24 | $33,987 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $19,462 |
| AristadaAripiprazole Lauroxil | 12 | $18,929 |
| Divalproex Sodium ErDivalproex Sodium | 349 | $16,745 |
| Lurasidone Hcl | 54 | $14,795 |
| Clozapine OdtClozapine | 21 | $9,115 |
| Aripiprazole | 245 | $6,386 |
| Ziprasidone Hcl | 106 | $5,316 |
| Paliperidone ErPaliperidone | 44 | $4,958 |
| Divalproex Sodium | 38 | $4,471 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 86 | $3,635 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $157 | $349,49444 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,165 | $287,18739 claims |
| Alkermes, Inc.Lybalvi, Aristada | $1,318 | $137,44389 claims |
| AbbVieVraylar | $669 | $53,15041 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $472 | $33,98724 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $40 | $19,46212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Visalia
- Thomas RoskoVisalia$389K
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.